Cannara Biotech Closes $17.6 Million Financing

Published: July 19, 2018

Cannara Biotech Closes $17.6 Million Financing

Cannara Biotech Inc. has closed a $17.66 million common share funding round. The financing furthers Cannara’s vision of creating one of the largest indoor medical cannabis growing facilities in North America. The proceeds will support the Phase 1 build-out at Cannara’s Farnham facility, as well as fund additional expansion and product development.

“The success of our financing initiative, which included a number of key opinion leaders in the Cannabis industry, is a vote of confidence in our strategy of defining and developing the Cannara brand to be synonymous with the highest quality medical Cannabis,” said Zohar Krivorot, President and CEO of Cannara. “We will continue to expand our production capacity with additional properties and select M&A activity. Product branding will play a prominent role in Cannara’s growth in the Cannabis marketplace.”

First Republic Capital was the sole broker for the offering. An existing Cannara shareholder, FSD Pharma’s investment in this round reinforces their commitment to Cannara’s strategic plan and their collaboration.

Cannara also announced it has appointed Lennie Ryer CPA, CA, CFE as CFO and Vice-President Finance. He will assist the Company in its transition from a development stage entity to a commercially successful company including leading all financing initiatives to further advance the Company’s capital market strategy.

“The extensive experience Lennie brings to Cannara is well-aligned with our financial objectives. He has led the financial strategy of numerous public and private companies in the biotech sector as CFO, advisor and Board Director,” said Zohar Krivorot. “Mr. Ryer will be an important member of the Cannara team as our financial profile changes and we transition to revenue growth.”

Mr. Ryer previously held the position of Chief Financial Officer and Vice-President of Finance at ConjuChem Biotechnologies, where he designed and executed offerings in excess of $345 million. Mr. Ryer was also the CFO and VP Finance at Paladin Labs, a specialty pharmaceutical firm, from 1999-2001. While at Paladin, Mr. Ryer helped transitioned the company to the Toronto Stock Exchange and led the company’s most significant financing initiative.